Established in 1943, Shandong Xinhua Pharmaceutical Co., Ltd. is the earliest established Chinese pharmaceutical company. We are mainly engaged in developing, manufacturing and marketing APIs, finished dosages, pharmaceutical intermediates and equipment.
Shandong Xinhua is a public company of H shares and A shares with sound capital structure and product mix. As one of the large-sized manufacture bases of API and pharmaceutical products in China and Asia, our company enjoys an impeccable reputation as the largest manufacturer and exporter of antipyretics and analgesics in Asia. Meanwhile, we are also an important manufacturer for anti-infective drugs for the central nervous system, and cardio cerebro-vascular system.
We are a historically-important enterprise. In 1950, we succeeded in developing sodium stubogluconate for stopping Kala-Azar, an epidemic that lasted several decades in northern China. In 1953, our company developed the first glass-lined reactor in China. We also started China's first API production line in 1954. In 1996, we were listed on the Hong Kong Stock Exchange, and in 1997 were added to the Shenzhen Stock Exchange.
Besides supplying to local clients, Shandong Xinhua has exported its products to more than 50 countries and regions with annual foreign earnings near USD100,000,000. Our company has been certified GMP, ISO10012, ISO9002 and ISO14001 with 6 products FDA approved and 7 products COS certified in European countries as of 2004. Our API capacity is 25,000 tons, pharmaceutical intermediates 40,000 tons and the capacity of diversified finished dosages are 8,000,000,000 tablets, 200,000,000 injections and 300,000,000 capsules.
Based on our "win-win" business policy, our long term goal is to become one of the key pharmaceutical companies in the world and to become a leading global supplier of API, pharmaceutical intermediates and generics.
Shandong Xinhua would like to explore all kinds of opportunities and establish long-term partnerships with friends and clients all over the world.
